Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 79% Improvement Relative Risk Case 14% c19hcq.org Belmont et al. NCT04354870 HCQ PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 80 patients in the USA Fewer symptomatic cases with HCQ (not stat. sig., p=0.21) Belmont et al., ClinicalTrials.gov, NCT04354870 Favors HCQ Favors control
COVID-19 PrEP HCW HCQ Study
Belmont et al., ClinicalTrials.gov, NCT04354870 (Preprint), NCT04354870 (history)
Belmont et al., COVID-19 PrEP HCW HCQ Study, ClinicalTrials.gov, NCT04354870 (Preprint), NCT04354870
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of HCQ prophylaxis in the USA, with 56 HCQ patients and 24 control patients, showing no significant differences. NCT04354870 (history)
risk of symptomatic case, 78.6% lower, RR 0.21, p = 0.21, treatment 1 of 56 (1.8%), control 2 of 24 (8.3%), NNT 15.
risk of case, 14.3% lower, RR 0.86, p = 1.00, treatment 4 of 56 (7.1%), control 2 of 24 (8.3%), NNT 84.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Belmont et al., 6 Oct 2021, prospective, USA, preprint, 1 author, trial NCT04354870 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit